Key clinical point : The use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) increases the risk for distant organ metastasis in patients with non—small-cell lung cancer (NSCLC) receiving chemotherapy, with the risk being much higher in patients without vs with chemotherapy-induced myelosuppression.
Major finding : Use vs non-use of rhG-CSF more than doubled the risk for distant organ metastasis (48.37% vs 26.23%; adjusted hazard ratio [HR] 2.33; P < .01), with the risk being much higher in patients presenting without vs with myelosuppression (HR 3.34; 95% CI 1.86-6.02 vs HR 0.71; 95% CI 0.17-2.94; Pinteraction < .01).
Study details : Findings are from a retrospective cohort study including 307 patients with NSCLC who underwent surgery and postoperative systemic chemotherapy, of which 246 patients received rhG-CSF treatment during chemotherapy.
Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.
Source: Wang Y et al. rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy. BMC Cancer. 2022;22:741 (Jul 7). Doi: 10.1186/s12885-022-09850-4